Abstract Details
|
Stephen Krieger, MD, FAAN
(Mount Sinai Dept of Neurology)
PRESENTER |
Dr. Krieger has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Krieger has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for EMD Serono. Dr. Krieger has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech. Dr. Krieger has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Krieger has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for TG Therapeutics. Dr. Krieger has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Krieger has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cycle. The institution of Dr. Krieger has received research support from Novartis. The institution of Dr. Krieger has received research support from Bristol Myers Squibb. The institution of Dr. Krieger has received research support from Biogen. The institution of Dr. Krieger has received research support from Sanofi. |
| Patricia Izbicki, PhD (Octave) | Dr. Izbicki has received personal compensation for serving as an employee of Octave. Dr. Izbicki has received personal compensation for serving as an employee of AbbVie. Dr. Izbicki has received personal compensation in the range of $0-$499 for serving as a Speaker with Palm Health Foundation. Dr. Izbicki has a non-compensated relationship as a Board Member with Giving Voice Initiative that is relevant to AAN interests or activities. Dr. Izbicki has a non-compensated relationship as a Board Member with Mind, Music, and Movement Foundation that is relevant to AAN interests or activities. |
| Kelly Leyden, MRes (Octave Bioscience) | Ms. Leyden has received personal compensation for serving as an employee of Octave. |
| Lynden Bajus (Octave Bioscience) | No disclosure on file |
| Daniel Peterson (Octave Bioscience) | No disclosure on file |
| Michael Schrier | No disclosure on file |
| Emily Ding | No disclosure on file |
| VIDYA KESHAVAN (Octave Bioscience) | No disclosure on file |
| Tamara Hoyt (Rocky Mountain MS Research Group) | Ms. Hoyt has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. |
| John F. Foley, MD, FAAN (Rocky Mountain MS Clinic) | The institution of Dr. Foley has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Octave. Dr. Foley has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. The institution of Dr. Foley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics . The institution of Dr. Foley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutics. The institution of Dr. Foley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sandoz. Dr. Foley has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. Dr. Foley has stock in InterPRO Bioscience. The institution of Dr. Foley has received research support from Biogen. The institution of Dr. Foley has received research support from Novartis. The institution of Dr. Foley has received research support from Octave. The institution of Dr. Foley has received research support from Genentech. The institution of Dr. Foley has received research support from Imstem. The institution of Dr. Foley has received research support from Aegir. |